secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001437749-23-023423
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics Q2 2023 net loss $9.8M; clinical enrollment milestones; CFO appointed
--------------------------------------------------------------------------------

- Cash at June 30, 2023: $99.4M, down from $110.9M at Dec 31, 2022.
- Net loss Q2 2023: $9.83M vs $6.67M Q2 2022; operating expenses $7.79M up 18% YoY.
- Impairment charge of $2.99M on investment in Dynamic Cell Therapeutics (DCT).
- Phase 2 EVANGELINE PK cohort fully enrolled; Karisma-Endoxifen 70% enrolled; I-SPY 2 30% enrolled.
- Appointed Greg Weaver as CFO; US patent granted for enterically encapsulated endoxifen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923023423/0001437749-23-023423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923023423/atos20230804_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer